KRAS and lung cancer: In the training cohorts of all the studies, the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) of radiomics for evaluating the KRAS status in lung cancer patients were 0.80 (95% CI: 0.76 - 0.83), 0.78 (95% CI: 0.75 - 0.82), 3.6 (95% CI: 3.0 - 4.3), 0.27 (95% CI: 0.22 - 0.33), and 13 (95% CI: 9 - 19), respectively.